

R E M A R K S

On January 16, 2008, the undersigned had a telephone interview with Examiner Pande and her supervisor, Examiner Strzelecka, to discuss (i) possible claim amendments and (ii) the Alexander and Raicht reference. The above claim amendments to claims 1 and 5 are based on said telephone interview.

The terminology of extracting RNA added to claim 1 is supported in the specification on page 8, line 3.

Page 5 of the specification and claims 3 and 18 were amended to add generic terminology for the terms "Isogene" and "Ultraspec II." The generic terminology for "Isogene" was taken from column 45, lines 42 to 44 of USP 6,797,483 (a copy of the first page and of columns 45 to 46 of which are enclosed). The generic terminology for "Ultraspec II" was taken from the publication of record entitled "Ultraspec™-II RNA Isolation System," Biotechx Bulletin, No. 28, (1993).

Withdrawn claims 7 to 12 were canceled hereinabove. Applicant reserves his right to file a Divisional application under 35 USC 121 directed to said claims.

It is respectfully submitted that Example 2 on pages 10 to 11 of the specification provides unexpected results for

applicants' present claims in comparison with the Alexander and Raicht reference of record.

Reconsideration is requested. Allowance is solicited.

An INFORMATION DISCLOSURE STATEMENT is being filed concomitantly herewith.

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Frishauf, Holtz, Goodman
& Chick, P.C.
220 Fifth Ave., 16th Floor
New York, NY 10001-7708
Tel. Nos. (212) 319-4900
Fax No.: (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

Respectfully submitted,



Richard S. Barth
Reg. No. 28,180

Encs.: (1) copy of cover page and columns 45 to 46
of USP 6,797,483

(2) INFORMATION DISCLOSURE STATEMENT